

**Table 7.6e**  
**Immunosuppression Use for Maintenance**  
**Prior to Discharge, 1999 to 2008**  
**Recipients with Pancreas After Kidney (PAK) Transplants**

|                                       | Year of Transplant |       |       |       |       |       |       |       |       |       |
|---------------------------------------|--------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|                                       | 1999               | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  | 2006  | 2007  | 2008  |
| <b>Functioning Graft at Discharge</b> | 206                | 278   | 287   | 336   | 315   | 380   | 306   | 255   | 240   | 193   |
| <b>With Immunosuppression Info</b>    | 203                | 277   | 286   | 335   | 312   | 375   | 303   | 249   | 230   | 192   |
| <b>Corticosteroids</b>                |                    |       |       |       |       |       |       |       |       |       |
| Any in Category                       | 90.1%              | 95.7% | 93.4% | 89.9% | 80.8% | 74.7% | 66.7% | 63.9% | 57.8% | 59.9% |
| Steroids                              | 90.1%              | 95.7% | 93.4% | 89.9% | 80.8% | 74.7% | 66.7% | 63.9% | 57.8% | 59.9% |
| <b>Cyclosporine</b>                   |                    |       |       |       |       |       |       |       |       |       |
| Any in Category                       | 14.3%              | 13.7% | 9.8%  | 11.3% | 8.3%  | 8.3%  | 6.6%  | 5.6%  | 4.8%  | 3.6%  |
| Sandimmune                            | 2.5%               | 2.2%  | 0.7%  | 0.6%  | 0.3%  | 0.5%  | 0.3%  | 0.0%  | 1.7%  | 0.0%  |
| Neoral                                | 11.3%              | 11.6% | 8.0%  | 9.0%  | 6.1%  | 5.6%  | 5.9%  | 5.2%  | 3.0%  | 3.1%  |
| Gengraf                               | 0.5%               | 0.0%  | 1.0%  | 1.8%  | 1.9%  | 2.1%  | 0.3%  | 0.4%  | 0.0%  | 0.5%  |
| <b>Tacrolimus</b>                     |                    |       |       |       |       |       |       |       |       |       |
| Any in Category                       | 83.3%              | 85.2% | 90.6% | 86.3% | 80.8% | 79.7% | 85.5% | 92.0% | 93.5% | 93.2% |
| Tacrolimus                            | 83.3%              | 85.2% | 90.6% | 86.3% | 80.8% | 79.7% | 85.5% | 92.0% | 93.0% | 92.7% |
| Everolimus                            | 0.0%               | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.4%  | 0.5%  |
| <b>Antimetabolites</b>                |                    |       |       |       |       |       |       |       |       |       |
| Any in Category                       | 85.2%              | 82.3% | 75.5% | 74.3% | 85.6% | 80.3% | 83.8% | 84.3% | 94.3% | 93.8% |
| Mycophenolate Mofetil                 | 81.8%              | 80.5% | 74.1% | 74.0% | 84.9% | 78.9% | 79.5% | 74.3% | 83.9% | 79.2% |
| Mycophenolate Sodium                  | 0.0%               | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 1.1%  | 3.3%  | 9.6%  | 9.1%  | 13.0% |
| Azathioprine                          | 3.4%               | 1.8%  | 1.4%  | 0.3%  | 0.6%  | 0.3%  | 1.0%  | 0.4%  | 1.3%  | 1.0%  |
| Leflunomide                           | 0.0%               | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.5%  |
| <b>mTOR Inhibitors</b>                |                    |       |       |       |       |       |       |       |       |       |
| Any in Category                       | 1.5%               | 8.3%  | 22.0% | 19.4% | 14.7% | 16.3% | 13.9% | 15.7% | 7.8%  | 7.8%  |
| Sirolimus                             | 1.5%               | 8.3%  | 22.0% | 19.4% | 14.7% | 16.3% | 13.9% | 15.7% | 7.8%  | 7.8%  |
| Everolimus                            | 0.0%               | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  | 0.0%  |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.